NDA 203100 · Gilead Sciences INC
Stribild
Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Disoproxil Fumarate · Oral · Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Cytochrome P450 3A Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Sep 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Aug 27, 2012
Approved uses
5
Original approval plus efficacy supplements
Registered trials
155
48 Phase 3, 6 recruiting
FAERS reports
8,967
7,687 serious, 144 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued EMTRIVA or VIREAD, which are components of STRIBILD. Hepatic function should be monitored closely, with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue STRIBILD. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and HBV who have discontinued EMTRIVA or VIREAD, two of the components of STRIBILD. Hepatic function should be monitored closely in these...
What it is approved for
From the label in effect Feb 4, 2025.
STRIBILD ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD [see Clinical Studies (14) ] . STRIBILD is a four-drug combination of elvitegravir, an HIV integrase strand transfer inhibitor (HIV-1 INSTI), cobicistat, a CYP3A inhibitor, and emtricitabine and tenofovir disoproxil fumarate (TDF), both HIV nucleoside analog reverse transcriptase inhibitors (HIV NRTI) and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD. ( 1 , 14 )
Mechanism: STRIBILD is a fixed-dose combination of antiretroviral drugs elvitegravir (boosted by the CYP3A inhibitor cobicistat), emtricitabine, and TDF [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 27, 2017 Supplement 25 · Efficacy · priority review LabelLetter
- Dec 17, 2014 Supplement 11 · Efficacy LetterLabel
- Aug 28, 2014 Supplement 10 · Efficacy LabelLetter
- Oct 2, 2013 Supplement 4 · Efficacy LetterLabel
- Aug 27, 2012 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelSummary ReviewPediatric CDTL ReviewPediatric Clinical Pharmacology Review
1 products under this application
- STRIBILD · COBICISTAT 150MG; ELVITEGRAVIR 150MG; EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
NCT02269917 · 1,149 participants · Start Mar 2015 · Primary completion Feb 2017
Drug: D/C/F/TAF; Boosted Protease Inhibitor (bPI) and 1 more · For: Human Immunodeficiency Virus Type 1
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 79 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01797445 · 872 participants · Start Mar 12, 2013 · Primary completion Sep 19, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01780506 · 872 participants · Start Dec 26, 2012 · Primary completion Aug 26, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
NCT02431247 · 725 participants · Start Jul 6, 2015 · Primary completion Mar 2, 2017
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC; DRV/COBI FDC and 4 more · For: Immunodeficiency Virus Type 1, Human
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 80 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01106586 · 708 participants · Start Apr 2010 · Primary completion Sep 2011
Drug: Stribild; ATV and 6 more · For: HIV; HIV Infections
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 146 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01095796 · 707 participants · Start Mar 2010 · Primary completion Aug 2011
Drug: Stribild; Atripla and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 102 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased4,603
- renal injury3,312
- skeletal injury3,030
- chronic kidney disease2,519
- tooth loss2,488
- bone loss2,161
- osteonecrosis2,117
- renal failure2,087
- multiple fractures1,980
- tooth injury1,979
- pain1,846
- emotional distress1,813
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 4 |
| 2013 | 82 |
| 2014 | 373 |
| 2015 | 278 |
| 2016 | 264 |
| 2017 | 231 |
| 2018 | 297 |
| 2019 | 539 |
| 2020 | 3,896 |
| 2021 | 1,444 |
| 2022 | 666 |
| 2023 | 317 |
| 2024 | 280 |
| 2025 | 259 |
| 2026 | 37 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Stribild (Elviteg/Cob/Emtri/Tenofo Disop)
2024 spending
$23.1M
Beneficiaries
632
5,111 claims
Per beneficiary
$36,621
$138.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,530,535 |
| 2021 | $37,194,003 |
| 2022 | $32,089,678 |
| 2023 | $27,932,986 |
| 2024 | $23,144,779 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Symtuza® in clinical practice.
Luis Casado J, Fontecha M, Monsalvo M, et al. · Enferm Infecc Microbiol Clin (Engl Ed) 2018 · Clinical Trial, Phase III
- Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, et al. · Eur J Cancer 2023 · Randomized Controlled Trial, Multicenter Study
- The Drug-Drug Interaction Profile of Presatovir.
Xin Y, Weng W, Murray BP, et al. · J Clin Pharmacol 2018 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM, Gordi T, Zhong L, et al. · J Clin Pharmacol 2016 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Gantner P, Hessamfar M, Souala MF, et al. · Clin Infect Dis 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.